{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:26:57Z","timestamp":1773408417545,"version":"3.50.1"},"reference-count":64,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T00:00:00Z","timestamp":1179964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drug\u2010eluting stents (DES) seemed likely to mitigate the problem of restenosis and have become the predominant stent deployed during percutaneous coronary intervention (PCI). Sustained concerns about the rate of stent thrombosis (ST), particularly very late ST (&gt;1 year following PCI) led to a meeting of the Circulatory System Devices Advisory Panel to address \u201con\u2010label\u201d and \u201coff\u2010label\u201d use as well as appropriate duration of dual antiplatelet therapy following DES. Over 40 presentations by members of the FDA, industry personnel, and leaders in the field of interventional cardiology helped set forth the body of data available on DES. Standardized definitions of ST created by the Academic Research Consortium were applied to existing randomized trials and registries. At the end of the 2\u2010day session, the consensus of the panel was that \u201con\u2010label\u201d DES use is not associated with increased incidence of death and myocardial infarction (MI), although it is associated with increased rates of very late ST. \u201cOff\u2010label\u201d use is associated with increased risk of death or MI when compared with \u201con\u2010label\u201d use. Insufficient data exist to determine the duration of clopidogrel that would minimize ST and bleeding risk, but the panel agreed with the current ACC\/AHA\/SCAI guidelines regarding dual antiplatelet therapy for at least 12 months in patients at low risk for bleeding, especially with \u201coff\u2010label\u201d use. More data from trials designed with better control arms and prespecified analyses of complex patients and lesions subsets over longer periods of follow\u2010up are needed. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ccd.21179","type":"journal-article","created":{"date-parts":[[2007,5,27]],"date-time":"2007-05-27T18:17:43Z","timestamp":1180289863000},"page":"1064-1074","source":"Crossref","is-referenced-by-count":46,"title":["Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug\u2010eluting stent thrombosis"],"prefix":"10.1002","volume":"69","author":[{"given":"Tina L.","family":"Pinto Slottow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Waksman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,5,24]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198703193161201"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104123441502"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408253310802"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812033392303"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.6.1676"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00641-6"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00334-3"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000140721.27004.4B"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012843"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2004.03.023"},{"key":"e_1_2_8_12_2","unstructured":"December 7 2006. Cordis Corporation Announces Clinical and Educational Programs for the CYPHER\u00ae Sirolimus\u2010eluting Coronary Stent. Available fromhttp:\/\/www.cordis.com\/active\/crdus\/en_US\/html\/cordis\/downloads\/press\/155_5130_1_FDA_Panel_PR.pdf. p Retrieved December 12 2006."},{"key":"e_1_2_8_13_2","unstructured":"January 19 2005. Boston Scientific Announces Implantation of Millionth TAXUS\u00ae Express2\u2122 Coronary Stent System. Available fromhttp:\/\/bostonscientific.mediaroom.com\/index.php?s=press_releases&item=451. p Retrieved December 12 2006."},{"key":"e_1_2_8_14_2","unstructured":"FarbA UchidaT DuggiralaHJ. FDA Summary Vol. 2007. FDA Circulatory System Devices Panel Meeting December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph1_17_FDA%20Summary.pdf."},{"key":"e_1_2_8_15_2","unstructured":"CamenzindE. Safety of Drug Eluting Stents: A Meta\u2010analysis of First Generation DES programs. In: World Congress of Cardiology 2006 Barcelona Spain September2006."},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl282"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2003.031419"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.20878"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.15.1967"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.09.079"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.17.2126"},{"key":"e_1_2_8_22_2","unstructured":"CutlipD. Stent Thrombosis after Drug\u2010Eluting Stenting: Impact of a New Standard Definition on Clinical Trial Results. In: TCT 2006 October2006 Washington DC."},{"key":"e_1_2_8_23_2","unstructured":"FiorentinoRP. Stent Thrombosis: The Implications of Broader DES Use December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph1_18_Fiorention\u2010FDA.pdf."},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60314-6"},{"key":"e_1_2_8_25_2","unstructured":"BaimDS. Boston Scientific Presentation: Part II: Real\u2010World Use of the TAXUS\u00ae Drug\u2010Eluting Stent System December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph1_16_Baim\u2010Boston%20pt2.pdf."},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.02.039"},{"key":"e_1_2_8_27_2","unstructured":"ChieffoA. Influence of Prolonged Dual Antiplatelet Use on Late Stent Thrombosis in a Large Real\u2010World Registry: The Milan\/Siegburg\/Naples Experience. In: TCT 2006 October2006 Washington DC."},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.170815"},{"key":"e_1_2_8_29_2","unstructured":"FDA Labeling. 2003. CYPHER\u2122 Sirolimus\u2010eluting Coronary Stent. Accessed on December 18 2006. Availiable athttp:\/\/www.fda.gov\/cdrh\/PDF2\/p020026c.pdf."},{"key":"e_1_2_8_30_2","unstructured":"FDA Labeling. 2003. TAXUS\u2122 Express 2\u2122 Paclitaxel\u2010Eluting Coronary Stent System. Accessed on December 18 2006. Available athttp:\/\/www.fda.gov\/cdrh\/pdf3\/P030025c.pdf."},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2003.10.002"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.04.007"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.70.1026"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.08.011"},{"key":"e_1_2_8_35_2","unstructured":"RogersC DohonoeD MauriL. Drug\u2010Eluting Stent Safety Profile: Stent Thrombosis December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph1_13_Rogers\u2010Cordis.pdf."},{"key":"e_1_2_8_36_2","unstructured":"BaimDS. Boston Scientific Presentation. Part I: On\u2010label Use of the TAXUS\u00ae Drug\u2010Eluting Stent System December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph1_15_Baim\u2010Boston.pdf."},{"key":"e_1_2_8_37_2","unstructured":"CohenSA. \u201cReal\u2010World\u201d Use of the CYPHER\u00ae Sirolimus\u2010Eluting Stent: Data from Randomized Controlled Trials and Registries December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph1_14_Cohen\u2010Cordis.pdf."},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.7.819"},{"key":"e_1_2_8_39_2","unstructured":"KuntzRE. Medtronic Vascular: Endeavor Safety Analysis December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph2_17_Kuntz.pdf."},{"key":"e_1_2_8_40_2","unstructured":"SudhirK. Abbott Vascular Drug Eluting Stent Program December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph2_18_Sudhir.pdf."},{"key":"e_1_2_8_41_2","unstructured":"MauriL. Planned Combined Safety Analysis for Biolimus A9 Stents December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph2_19_Mauri.pdf."},{"key":"e_1_2_8_42_2","unstructured":"MichelsonA. Late Stent Thrombosis After DES: Role of Platelet Function Testing December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph1_02_Michelson.pdf."},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11078-6"},{"issue":"9","key":"e_1_2_8_44_2","first-page":"I371","article-title":"Comparing long\u2010term survival of patients with multivessel coronary disease after CABG or PCI: Analysis of BARI\u2010like patients in northern New England","volume":"112","author":"Malenka DJ","year":"2005","journal-title":"Circulation"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2006.04.044"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040316"},{"key":"e_1_2_8_47_2","unstructured":"GuytonRA. History of Evidence Based Coronary Revascularization\u2010Can we identify our mistakes and not repeat them? December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph2_12_Guyton.pdf."},{"key":"e_1_2_8_48_2","unstructured":"FergusonTB. Summary Recommendations to FDA: Society of Thoracic Surgeons' Perspective December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph2_13_Ferguson.pdf."},{"key":"e_1_2_8_49_2","unstructured":"SmithPK. Relative Merits and Clinical Selection of CABG Bare Metal Stents and Drug Eluting Stents in Practice and in Evolution December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph2_11_Smith.pdf."},{"key":"e_1_2_8_50_2","unstructured":"DoveJT. American College of Cardiology Testimony December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph2_20_Dove.pdf."},{"key":"e_1_2_8_51_2","unstructured":"DehmerGJ. The Society for Cardiovascular Angiography and Interventions Public Statement to the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph2_21_Dehmer.pdf."},{"key":"e_1_2_8_52_2","unstructured":"SmithS. The American Heart Association Public Statement to the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee. In: FDA Circulatory System Devices Panel Meeting December 7\u20108 2006 Gaithersburg MD."},{"key":"e_1_2_8_53_2","unstructured":"WallentinL LagerqvistB. Long\u2010term outcome of DES vs BMS implanted in Sweden 2003\u20102004 December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph1_07_Wallentin.pdf."},{"key":"e_1_2_8_54_2","unstructured":"MishkelGJ. Prairie \u201cReal World\u201d Drug Eluting Stent Database December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph2_06_Mishkel.pdf."},{"key":"e_1_2_8_55_2","unstructured":"MagidD. Longitudinal Outcomes Following Drug Eluting Stent Implantation December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph2_04_Magid.pdf."},{"key":"e_1_2_8_56_2","unstructured":"WilliamsDO. Comparisons of Drug\u2010Eluting to Bare Metal Stents: Findings from the NHLBI\u2010Dynamic and the DEScover Registries December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph2_05_Williams.pdf."},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.667915"},{"key":"e_1_2_8_58_2","unstructured":"WaksmanR. DES Thrombosis: Results from Contemporary Registries at the Washington Hospital Center December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph2_08_Waksman.pdf."},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.2.joc60179"},{"key":"e_1_2_8_60_2","unstructured":"KongDF. Drug\u2010Eluting vs. Bare Metal Stents: Results from a Practice\u2010Based Registry December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph2_03_Kong.pdf."},{"key":"e_1_2_8_61_2","unstructured":"MehranR. A Prospective \u201cAll Comers\u201d Single Arm Study in Complex Patients: The MATRIX Trial December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph2_02_Mehran.pdf."},{"key":"e_1_2_8_62_2","unstructured":"KimuraT MitsudouK NobuyoshiM. Preliminary One\u2010Year Outcome After Sirolimus\u2010Eluting Stent Implantation: The j\u2010Cypher Registry Update December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph1_10_Kimura.pdf."},{"key":"e_1_2_8_63_2","unstructured":"BrowningJA BurkeN MenssenKM NewellMC MooneyMR LipsDL Vazquez\u2010BenitezG DuvalS HenryTD. Impact of DES in STEMI: The Minneapolis Heart Institute Level 1 MI Program December 7\u20108 2006 Gaithersburg MD. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006\u20104253oph2_14_Henry.pdf."},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2411"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.21179","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.21179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T06:52:28Z","timestamp":1700031148000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.21179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,24]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1002\/ccd.21179"],"URL":"https:\/\/doi.org\/10.1002\/ccd.21179","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,24]]}}}